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ABSTRACT
Objectives: To establish if emergency medicine and
neuroscience specialist consultants have different risk
tolerances for investigation of suspected spontaneous
subarachnoid haemorrhage (SAH), and to establish if their
risk–benefit appraisals concur with current guidelines.
Setting: 4 major neuroscience centres in London.
Participants: 58 consultants in emergency medicine
and neuroscience specialities (neurology, neurosurgery
and neuroradiology) participated in an anonymous
survey.
Primary and secondary outcome measures:
The primary outcome measure was the highest stated
acceptable risk of missing SAH in the neurologically
intact patient presenting with sudden onset headache.
Secondary outcome measures included agreement with
guideline recommendations, risk/benefit appraisal and
required performance of diagnostic tests, including
lumbar puncture.
Results: Emergency department clinicians accepted
almost 3 times the risk of a missed SAH diagnosis
compared with the neuroscience specialists (2.8% vs
1.1%; p=0.02), were more likely to accept a higher risk
of missed diagnosis for the benefit of a non-invasive
test (p=0.04) and were more likely to disagree with
current published guidelines stipulating the need for
LP in all CT-negative cases (p=0.001).
Conclusions: Divergence from recognised procedures
for SAH investigation is often criticised and attributed
to a lack of knowledge of guidelines. This study
indicates that divergence from guidelines may be
explained by alternative risk–benefit appraisals made by
doctors with their patients. Guideline recommendations
may gain wider acceptance if they accommodate the
requirements of the doctors and patients using them.
Further study of clinical risk tolerance may help explain
patterns of diagnostic test use and other variations in
healthcare delivery.
INTRODUCTION
Controversies in the investigation of sus-
pected spontaneous subarachnoid haemor-
rhage (SAH) principally concern the
question of whether or not a lumbar punc-
ture (LP) is needed following a normal CT
scan. Missing the chance to treat acute ane-
urysmal SAH can have devastating conse-
quences due to high associated mortality and
morbidity.1 2 Although an imperfect test,3 4
the LP is held as a gold standard in the diag-
nosis of SAH, and when combined with CT
has been shown to detect SAH reliably.5
Current international and national guide-
lines assert that SAH cannot be excluded
based on a negative CT scan. Investigation is
deemed incomplete unless negative imaging
is followed by a lumbar puncture with spec-
trophotometric assessment of the super-
natant for cerebrospinal ﬂuid bilirubin.2 6–9
UK-based studies have found frequent devi-
ation from guidelines. LP omission rates of
40–50% are common and are only slightly
lower in teaching hospitals compared with
District General Hospitals.10–13 UK ﬁgures
are in line with international practice where
rates of LP omission range between 40% and
60%.14–16
Although guidelines are not ‘railroads’ for
clinicians to follow,17 omission of LP in
Strengths and limitations of this study
▪ Novel survey addressing a controversial clinical
scenario commonly encountered by all acute
medical physicians.
▪ Explanation for variation in clinical practice that
has been widely criticised and has a profound
impact on patients, doctors and healthcare
institutions.
▪ Pilot survey with a modest sample size (n=58).
▪ No suitable validated instrument was available to
measure clinicians’ risk tolerance.
▪ Potential participation bias due to low response
rate.
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suspected SAH diagnosis has been widely criti-
cised,8 10 11 18 and attributed to a lack of awareness and
education.10 14 However, the role of LP has been called
into question due to reported low speciﬁcity, low clinical
impact, low diagnostic yield and improved sensitivity of
modern CT.3 4 19–23 Doctors are also known to vary in
their tolerance of risk and uncertainty which may inﬂu-
ence management decisions.24–26 The low LP rate in sus-
pected SAH may therefore represent widespread
disagreement with guidelines and greater tolerance of
the risk of misdiagnosis. A fear of LP-related complica-
tions may also dissuade clinicians from performing or
recommending the procedure.21
Guidelines for SAH investigation have been shown to
be relatively risk intolerant compared with recom-
mended investigations of other potentially fatal condi-
tions presenting to the emergency department (ED),
for example, pulmonary embolism (PE) and acute cor-
onary syndrome (ACS). Guidelines for suspected PE and
ACS allow small but non-zero calculated risk end points,
while SAH guidelines afford no misses.27 ED clinicians
habituated to accept small risks of misdiagnosis for
common emergency presentations (such as PE and
ACS), may be more willing to accept similar risks in SAH
work-up compared with their neurospeciality colleagues
(ie, neurologists, neurosurgeons and neuroradiologists).
Given that patients with suspected SAH are typically
managed by emergency physicians,28 any such variation
in risk appraisal could help explain the frequency of
LP omission.
The purpose of this study is therefore twofold:
1. to survey clinicians’ analysis of risk and beneﬁt
related to investigation of suspected acute spontan-
eous SAH;
2. to establish whether published guidelines reﬂect
current professional opinion, and to characterise any
variation between ED clinicians and neurospecialists.
The null hypothesis is that ED clinicians are no more
risk tolerant than neurospecialist consultants.
Given an LP omission rate of between 40% and 50%
in the UK, at least 40% of ED clinicians are expected to
disagree with the guideline stating that LP is required in
CT-negative cases.
METHODS
No appropriate validated instruments were available to
measure risk tolerance for missed SAH diagnosis. We
therefore elected to design a questionnaire for this
purpose according to principles described in detail else-
where (see online supplementary material).29 30 The
questionnaire underwent initial trial use by consultant
and trainee clinicians in the relevant specialities.
Changes were made to wording, question format and
layout following this exercise.
Each question was devised to investigate clinicians’
perceptions about aspects of the diagnostic process: clin-
ical risk factors; LP complications; risk tolerance for
misdiagnosis; sensitivity requirements of diagnostic tests;
risk–beneﬁt appraisal for diagnostic tests and investiga-
tive inertia, that is, the propensity to pursue a diagnosis
due to referral bias rather than personal appraisal.
While piloting the questionnaire, it became apparent
that respondents could be identiﬁed if they provided
their age, gender and speciality. Demographic details
were therefore limited to include age range (<40, 41–50,
51–60, >60) and speciality but not gender.
The primary outcome of risk tolerance was measured
using a short vignette describing an otherwise well adult
aged 40 years, presenting with a worst-ever ‘thunderclap
headache’. Participants were asked to give the post-test
probability of missed SAH that they would accept before
stopping further investigations. Respondents were told
that the pretest probability for patients was 10%, a con-
servative estimate and in line with similar clinical scen-
arios in the published literature.31
The primary objective of this study was to investigate
patterns of risk tolerance and guideline agreement
between neurospecialists and emergency physicians. A
lack of validated instruments and relevant preliminary
data prohibited a power calculation. We opted to sample
two groups (neurospecialists and emergency physicians)
comprising a quota target of 50 respondents, half from
each group. Consultant neurosurgeons, neurologists,
neuroradiologists and emergency clinicians were
approached at four large NHS Trusts with tertiary neuro-
science services: UCLH, Kings College Hospital, Queens
Hospital Romford and Charing Cross/St Mary’s
Hospital. London Trusts were chosen to reduce the
inﬂuence of regional variations.
A written questionnaire was devised in preference to
an electronic survey because of concerns that electronic
correspondence would be missed or ignored among the
large volumes of information received electronically by
NHS consultants.
Permission to conduct the survey was then sought
from the clinical lead in each department. Invitations
to participate were communicated by telephone, email
and in person wherever possible in order to optimise
participation. Secretarial staff were approached to help
disseminate the questionnaires and email reminders
were sent to eligible consultants where necessary. Data
collection was carried out between October 2015 and
February 2016.
Statistical analysis
Data were entered into an Excel spreadsheet (Excel for
Mac, 2011). The signiﬁcance of group differences was
calculated using χ2 statistical tests within Excel. The stat-
istical package (StatPlus) was used for descriptive statis-
tics and for the t-test statistic where appropriate.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in
developing plans for recruitment, design or
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implementation of the study. No patients were asked to
advise on interpretation or the writing up of results.
RESULTS
A total of 58 consultants completed the questionnaire,
including 23 ED clinicians and 35 neuroscience specia-
lists. The overall response rate was 34% with propor-
tional participation by both subgroups (35% for the
neurospecialists compared with 32% of ED physicians).
The median age range was 41–50 years and consultants
had a median of 16–25 years of postgraduate experi-
ence. The gender of participants was not available for
reasons described above. A total of 17 questions (1.5%)
were omitted or ignored by the 58 respondents. A
further seven responses were excluded from analysis
because they were incompatible with the question asked,
indicating a misunderstanding or misreading.
Seventeen ED clinicians and 30 neurospecialists indi-
cated their risk tolerance for missed SAH diagnosis by
recording the highest post-test probability at which they
would stop investigations to diagnose SAH (Question
10). There was a signiﬁcant difference in the mean
scores between groups (p=0.03) with the ED clinicians’
risk tolerance almost three times higher than the neuro-
specialists’ (2.8% (SD 3.3) vs 1.1% (SD 1.9)).
Neurospecialists were also more likely to advocate
routine LPs compared with ED clinicians (74% vs 39%,
p=0.01).
Only 70% of consultants agreed with current guide-
lines stipulating that an LP is mandatory in suspected
SAH when an initial CT is negative (table 1). There was
a signiﬁcant difference between the ED and neurospe-
cialist groups in this regard with a majority of the ED
group disagreeing with guidelines (57%) compared with
a minority (11%) of neurospecialist consultants
(p<0.001). ED clinicians were more inclined to omit the
LP if a negative CT had been obtained within 6 hours of
headache onset (35% vs 3%, p=0.002).
ED consultants also required a higher pick-up rate to
justify the routine use of LP compared with their neuro-
specialist colleagues, but this difference did not achieve
statistical signiﬁcance (table 2).
There was no signiﬁcant group difference between the
clinicians’ personal experiences of LP-related
complications with both groups median estimate falling
in the ‘infrequent’ (1 in 200) category (ﬁgure 1).
Fewer than 10% of respondents in each group indi-
cated a willingness to substitute the LP in favour of a
cheaper or quicker test if it carried an increased
risk of missed diagnosis. However, ED clinicians were
more likely to accept an increased risk of misdiagnosis
for the beneﬁt of a non-invasive test (38% vs 11%,
p=0.02).
Almost all clinicians in both groups reported direct
personal experience of missed SAH due to incomplete
investigation (91% in both groups). Fifty-ﬁve per cent of
clinicians had given evidence in a medicolegal capacity
and although this was more common among ED clini-
cians (65% vs 55%), the difference was not statistically
signiﬁcant.
Local practices and policies were inﬂuential in decid-
ing work-up of SAH; however, personal experience was
the most commonly cited factor by clinicians (illustrated
in ﬁgure 2). Nevertheless, 22% of clinicians reported
that they would feel obliged to investigate SAH if it had
been raised and documented as a potential diagnosis,
irrespective of their own clinical judgement.
Although free text answers were not requested from
participants, some responses were annotated. Where
relevant, these are discussed below.
DISCUSSION
Although SAH is a relatively rare disease, its misdiagnosis
was a familiar scenario for more than 90% of consul-
tants. The consequence of missed diagnosis can be dev-
astating for patients and carries signiﬁcant medicolegal
implications for doctors and healthcare institutions. It is
therefore difﬁcult to understand the frequency with
which clinicians stray from recommended practice, espe-
cially considering the defensive nature of modern
medicine.32
There is an extensive body of published research
evaluating the appropriateness of different strategies for
SAH diagnosis. While there is some controversy regard-
ing the utility of LP in the diagnostic pathway, current
national and international guidelines unanimously rec-
ommend the procedure for patients with negative initial
imaging. A recent survey of UK Emergency and Acute
Table 1 Agreement with guidelines
Question/dimension
All clinicians combined
(n=58)
ED physicians
(n=23)
Neurospecialists
(n=35) p Value
LP mandatory ‘No’ 17 (30%) 13 (57%)* 4 (11%)
LP mandatory ‘Yes’ 40 (70%) 9 (39%)* 31 (89%) 0.0001
LP omitted when CT <6 hours ‘No’ 46 (84%) 15 (65%) 31 (89%)†
LP omitted when CT <6 hours ‘Yes’ 9 (16%) 8 (35%) 1 (3%)† 0.0017
*Question omitted by one consultant.
†Question omitted by three consultants.
LP, lumbar puncture.
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medicine clinicians conﬁrms a wide variation in practice
with only 74% of respondents following the recom-
mended CT-LP pathway.33
To the best of our knowledge, this is the ﬁrst study to
investigate whether clinicians’ risk tolerance might
account for the observed variation in practice and to
Table 2 Clinicians’ risk–benefit appraisals
Question/dimension
All clinicians combined
(n=58)
ED physicians
(n=23)
Neurospecialists
(n=35) p Value
Routine LP justified? ‘No’ 23 (40%) 14 (61%) 9 (26%)
Routine LP justified? ‘Yes’ 35 (60%) 9 (39%) 26 (74%) 0.007
Investigative inertia ‘No’ 45 (78%) 20 (87%) 25 (71%)
Investigative inertia ‘Yes’ 13 (22%) 3 (13%) 10 (29%) 0.2
Required LP pick-up rate: ≥1 SAH every
100 LPs
25 (44%) 12 (52%) 13 (38%)*
1 SAH every 101–500 LPs 19 (33%) 8 (35%) 11 (32%)*
1 SAH for every >500 LPs 13 (23%) 3 (13%) 10 (29%)* 0.3
Risk–benefit trade off†
Non-invasive test
Yes 12 (21%) 8 (38%)‡ 4 (11%) 0.018
No 44 (79%) 13 (62%)‡ 31 (89%)
Quicker test
Yes 5 (9%) 2 (10%)‡ 3 (9%)* 0.9
No 50 (89%) 19 (90%)‡ 31 (89%)*
Cheaper test
Yes 5 (9%) 2 (10%)‡ 3 (9%)* 0.9
No 50 (89%) 19 (90%)‡ 31 (89%)*
Experience of previous missed SAH ‘No’ 5 (9%) 2 (9%) 3 (9%)*
Experience of previous missed SAH ‘Yes’ 52 (91%) 21 (91%) 31 (91%)* 0.9
*Question omitted by one consultant.
†Participants were asked if they would accept a higher risk of missed SAH in the given scenarios: quicker, cheaper or non-invasive test.
‡Question omitted by two consultants.
LP, lumbar puncture.
Figure 1 Clinicians’ estimated frequency of lumbar puncture complications. Ordinal scale provided: Very rare is <1 in 200; Rare
∼1 in 500; Infrequent ∼1 in 200; Common ∼1 in 100; Very common ∼1 in 20.
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survey clinicians’ appraisals of the relevant recommenda-
tions directly.
Almost all respondents had a personal experience of
missed SAH diagnosis; however, only 70% agreed with
the guidelines that LP was mandatory for all CT-negative
cases. When ED clinicians were considered separately,
only 39% held this view. Previous attempts to explain
deviation from guidelines have suggested lack of aware-
ness as a possible cause. Taken together, our ﬁndings
suggest that clinicians are well aware of the perils of
missed diagnosis, but are nevertheless sceptical of the
beneﬁts of LP in the diagnostic pathway.
It is typically the emergency and acute medical physi-
cians who are compelled to perform an LP before refer-
ring or discharging patients with suspected SAH.
Neurospecialists are more likely to be involved in an
advisory capacity until a diagnosis has been made. The
LP may therefore serve as a ﬁlter reducing unnecessary
referral to specialist services.3 ED consultants were more
willing to trade off beneﬁts of a non-invasive diagnostic
test against the increased risk of missed diagnosis.
Neurospecialists did not tend to share this view, which
may reﬂect a concern that referrals would increase if
alternative tests were more readily performed.
This survey was not designed to test clinicians’ knowl-
edge of guidelines, epidemiology of SAH or the per-
formance of diagnostic tests. Nevertheless, some
responses did highlight common misconceptions, which
are worth addressing here. Although the LP is taken as a
gold standard test, the actual sensitivity in CT-negative
SAH is unknown.28 The commonly quoted sensitivity of
photospectrometry for xanthochromia comes from
Vermeulen et al34 who reported 100% sensitivity up until
2 weeks after ictus (n=32). These data were derived from
LPs performed in patients with CT-positive SAH.34 The
sensitivity of LP in CT-negative patients would be a more
useful measure since this is the context in which the LP
is employed. Unfortunately, this is difﬁcult to quantify
since there is no conﬁrmatory test against which the LP
can be measured.
The high frequency of equivocal photospectrometry
ﬁndings is another shortcoming of the LP. In a large
observational study by Sayer et al,4 more than 15% of
1898 LPs were inconclusive by Clinical Biochemistry
Guidelines.35 This large contemporary sample is argu-
ably more representative of current clinical practice
than the Vermulen cohort and demonstrates that even
when applying the CT-LP paradigm, SAH cannot be
entirely excluded. This may explain why ED clinicians
are less likely to consider the LP as a prerequisite for
SAH diagnosis.
Recent research has suggested that CT approaches
100% sensitivity in acute SAH if performed within
6 hours of ictus. This has led to calls for a change of
practice.36–39 Participants were speciﬁcally asked about
this scenario. ED clinicians were more willing to adopt
this policy than their neurospecialist counterparts,
which may reﬂect a desire to reduce pressure on EDs.
The concept of safe discharge has been deemed
‘irrational unhelpful and unachievable’ because it raises
unrealistic expectations of a risk-free environment.40
Conversely, accepting an arbitrary threshold for risk may
seem callous or even negligent as it consigns some
patients to an adverse outcome.41 Interestingly, ﬁve neu-
rospecialists stated that they would only stop investiga-
tions for SAH when the risk of missed diagnosis was
reduced to zero. None of the ED consultants shared this
view. ED clinicians’ reluctance to resort to LP may there-
fore reﬂect the greater tolerance of risk in this group.
It is arguably inappropriate—for patients and health
services—that a medical intervention should be deter-
mined entirely by the risk threshold of an individual
doctor.41 However, it is equally undesirable for guide-
lines to impose an arbitrary risk threshold that is based
Figure 2 Factors reported to
influence work up of
subarachnoid haemorrhage.
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on opinion rather than evidence. To be accepted by clin-
icians and patients, guidelines may need to accommo-
date a range of possible risk tolerance preferences. This
may apply to a variety of clinical situations—involving
different specialities and healthcare systems—where
there is a ﬁne balance between clinical risk and beneﬁt.
Our ﬁndings suggest that the current guidelines do
not closely reﬂect ED clinicians’ risk tolerance for SAH
investigation—despite the fact they usually manage
patients presenting with the acute sudden onset head-
ache. Incidentally, the Royal College of Emergency
Medicine was not represented in the formulation of the
current RCP Stroke guidelines (conﬁrmed by personal
correspondence).
Limitations of this study
The lack of an appropriate instrument to measure clini-
cians’ risk tolerance necessitated the development of a
novel questionnaire. Despite our best efforts, the
responses indicated some shortcomings of this tool that
limit the strength of our data. Seven respondents were
known to have misinterpreted questions because the
answers they provided were incompatible with the ques-
tion asked. Although these responses could be excluded
from the ﬁnal analysis, other misrepresentative responses
may still exist within the data set. The development and
validation of an instrument to reliably measure risk toler-
ance was outside the scope of this study. Although we did
not feel the lack of such a tool precluded investigation,
our ﬁndings require cautious interpretation as a result.
A targeted approach to recruitment (by email, tele-
phone or in person) was adopted to optimise participa-
tion. However, this may have introduced a degree of bias
since not all respondents were contacted in exactly the
same manner or at the same time. An online survey may
have generated more responses and would have been
easier to conduct at a national level but would not have
overcome participation bias. We felt a targeted pilot
survey was an appropriate starting point that could be
used to inform future study.
The survey is limited by a poor response rate, which
introduces the possibility of participation bias. Although
response rates were similar between the two groups, dif-
ferent factors may have inﬂuenced each group.
Response rates were not balanced across institutions
(ranging between 17% and 42%) and as such, our
results are skewed towards the NHS Trust that provided
the most responses.
As with any survey of this type, hypothetical scenarios
can never accurately reﬂect real-life practice. This
problem is exaggerated when considering abstract con-
cepts such as risk. We asked respondents to quantify
their acceptable risk of missed diagnosis. This is a par-
ticularly challenging task—reﬂected in the fact that four
consultants did not provide a response. Clinicians may
have felt uncomfortable characterising their clinical
judgement in statistical terms. However, this is a
common scenario faced by clinicians in their daily
practice when patients ask them to quantify the chance
of complications from an invasive procedure, diagnostic
test or surgery. Furthermore, incorporating relevant
quantitative research ﬁndings into clinical decision-
making is necessary to deliver evidence-based medicine
(EBM). Therefore, although a simulation, the scenario
we presented to clinicians is a realistic challenge similar
to that commonly faced in the healthcare setting.
One respondent indicated that they would ask the
patient to determine their own level of acceptable risk
rather than assume this responsibility for themselves. It
is possible that other participants shared a similar view
and felt our question was incompatible with their own
professional approach. This raises interesting questions
about the doctor–patient relationship, the didactic
nature of guidelines and the role of patients in guideline
development. Clearly, clinical risks need to be accept-
able to patients ﬁrst and foremost and patient centred-
ness has become a dominant paradigm in modern
medicine.42 However, transferring responsibility to the
patient can only lead to empowerment if patients are
supported in the decision-making process and the best
evidence is made easily accessible to them.
Patient participation is encouraged in guideline devel-
opment43 on the assumption that active patient involve-
ment will enhance the quality of guidelines. However, it
has been argued that this mechanism is ill suited to
achieving patient-centred care at the individual level. As
described by van de Bovenkamp and Trappenburg,42
training and supporting patients to participate as full
members in guideline development is a double-edged
sword. Patients who have been adequately trained and
supported become fellow academics and may no longer
be able to contribute the experiential knowledge for
which they were asked to participate in the ﬁrst place.
Patients who were not properly trained do contribute
this experiential knowledge, but studies have shown that
it is difﬁcult to incorporate this in EBM guidelines.
Clinicians continue to play a key role in guiding
patients through complex medical decisions. Although
challenging, further study of clinicians’ risk–beneﬁt
appraisals could improve our understanding of clinical
behaviours and ensure that guidelines and doctors work
together to deliver patient-centred care.
Knowledge of clinicians’ risk tolerance could also
inform diagnostic test development, given that the use-
fulness of a test is determined by more than its accuracy
alone. For example, our ﬁndings suggest that some clini-
cians would prefer a non-invasive alternative to LP,
despite a lower sensitivity. Conversely, a diagnostic test
offering improved accuracy may fail to gain acceptance
if other characteristics were less tolerable to doctors and
patients. This is borne out by the growing use of non-
invasive vascular imaging techniques in SAH diagnosis.
Considerable advances in non-invasive vascular imaging
methods such as CT angiography (CTA) and MR angiog-
raphy (MRA) have led to their use in clinical practice. A
CT/CTA diagnostic paradigm has been reported to have
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a sensitivity of 99% for aneurysmal SAH diagnosis and
has been proposed as a substitute for LP.44 Opponents
criticise this approach for moving from the diagnosis of
haemorrhage to the detection of aneurysms, which may
be coincidental.45 Nevertheless, given the advantages
afforded by non-invasive tests, the use of CTA and MRA
may need to be incorporated into future guidelines for
the management of patients with suspected SAH.
Conclusion
This study provides a possible explanation for the
observed variation in practice of SAH investigation.
Opinions vary signiﬁcantly between ED clinicians and
neurospecialists with respect to the utility of LP and
their tolerances for the risk of missed diagnosis.
Omission of the LP from the diagnostic work-up may
reﬂect scepticism about its utility rather than an
unawareness of the risk of missed diagnosis.
Guidelines provide essential, expert evidence summar-
ies and can marshal clinicians through a complex and
ever-changing scientiﬁc literature. Nevertheless, guide-
lines, healthcare institutions, clinicians and patients may
continue to contradict each other when they are
informed by different tolerances of risk. Guidelines may
be used more widely if they accommodate different pre-
ferences where appropriate.
Future study of risk tolerance in the clinical setting
may enhance our understanding of a range of clinical
behaviours, including referral patterns and diagnostic
test use. Development of validated instruments to
measure risk tolerance is needed, so that robust conclu-
sions can be drawn from future research.
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